Moderna Shares Rise Over 14% Following Trial Results
Shares of Moderna (MRNA) surged more than 14%, closing at $158.52 on Tuesday after the company released positive trial results that led to a repricing in investor sentiment. The biotechnology firm, based in Cambridge, Massachusetts, saw its stock climb by nearly $19.63 during the session. This significant gain follows an even larger 177% jump recorded earlier this year on August 19 when Moderna partnered with Merck (MRK). Investors are responding positively to new data that could enhance the company's growth prospects and market valuation.
Topics: biotechnology Moderna MRNA stock rally